International clinical registry of patients with chronic myeloid leukaemia.
start of the project: January 2004
end of the project: April 2023
The CAMELIA project (Chronic MyEloid LeukaemIA) is focused on monitoring of patients with chronic myeloid leukaemia (CML) in everyday clinical practice. Its aim is to monitor all CML patients in participating haemato-oncology centres, regardless of their treatment modalities.
The project was initiated at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and has continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.
The structure of monitored data has been designed in a way which makes it possible to collect data on three levels:
Since the very beginning in 2005, the CAMELIA project has been organized as an international project: haemato-oncology centres from the Czech Republic and Slovakia are involved. The project aims to coordinate the procedures in CML treatment, taking into account international guidelines as well as possibilities of participating centres. The CAMELIA project is open for further cooperation: its background and coordination are ready to be extended for other interested parties.
The CAMELIA project is closely linked to international projects focused on the issues related to leukaemias; through the mediation of participating institutions, the project is part of the European LeukemiaNet and the EUTOS for CML project.
Other important information:
CAMELIA CZ as part of the CAMELIA project was finished in 2021, and CAMELIA SK was finished in 2023.